The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Acute Care Syndromic Testing Market Through 2030?
The acute care syndromic testing market has demonstrated rapid expansion in recent years. This market is projected to grow from $4.59 billion in 2025 to $5.17 billion in 2026, at a compound annual growth rate (CAGR) of 12.8%. The historical growth can be attributed to several factors, including the demand for emergency infection diagnosis, the expansion of hospital ICUs, initiatives for outbreak preparedness, the adoption of molecular diagnostics, and the optimization of critical care workflows.
The acute care syndromic testing market size is predicted to experience swift growth over the upcoming period. It is expected to expand to $8.3 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.5%. This projected increase is driven by elements such as AI-enabled syndromic panels, the broadening of emergency testing, antimicrobial stewardship initiatives, point-of-care molecular systems, and a sharpened focus on pandemic preparedness. Significant trends expected during this forecast include rapid multiplex pathogen detection, molecular testing within emergency departments, multi-disease panels utilizing single samples, enhanced clinical decision support, and a reduction in diagnostic turnaround time.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
Which Major Factors Are Contributing To The Development Of The Acute Care Syndromic Testing Market?
The rising occurrence of infectious diseases is anticipated to stimulate the acute care syndromic testing market moving forward. Infectious diseases are illnesses stemming from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, which possess the ability to spread between individuals, animals, or through the environment. The increasing prevalence of infectious diseases is fueled by factors including population growth, urbanization, international travel, antimicrobial resistance, and climate change, thereby amplifying the necessity for effective prevention and treatment. Acute care syndromic testing is employed in infectious diseases to rapidly identify pathogens and co-infections through multiplex molecular diagnostics, facilitating precise treatment decisions. For instance, in February 2024, according to the Health Security Agency, a UK-based government agency, week 4 of 2024 saw the influenza positivity rate climb to 16.6%, an increase from 14.0% the previous week. Consultations for influenza-like illness (ILI) also rose, reaching 9.8 per 100,000 people, compared to 7.5 per 100,000 in the prior week. Additionally, influenza hospitalizations ascended to 7.63 per 100,000, up from 5.12 per 100,000 the week before. Thus, the escalating incidence of infectious diseases is a key driver for the acute care syndromic testing market.
What Key Segment Areas Are Included In The Acute Care Syndromic Testing Market Assessment?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Which Trends Are Expected To Shape The Acute Care Syndromic Testing Market?
Major companies within the acute care syndromic testing market are concentrating on technological progress, particularly multiplex real-time polymerase chain reaction (PCR) technology, to improve diagnostic accuracy, facilitate rapid pathogen detection, streamline laboratory workflows, decrease turnaround time, and better patient outcomes via precise and prompt treatment. Multiplex real-time PCR technology represents a sophisticated molecular diagnostic approach that simultaneously identifies and quantifies several pathogens or genetic targets in a single PCR reaction, boosting the efficiency and accuracy of disease diagnosis. For example, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research company, launched the QIAstat-Dx syndromic testing solution in Japan, which includes a SARS-CoV-2 respiratory panel that can detect over 20 pathogens from a single sample. Utilizing multiplex real-time PCR technology, this system delivers quick results with minimal labor in contrast to individual PCR assays. The system is available in over 100 countries, thereby increasing the worldwide accessibility of syndromic testing.
Who Are The Major Companies Operating In The Acute Care Syndromic Testing Market?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
Access The Complete Acute Care Syndromic Testing Market Report:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
Which Region Contributes The Most To The Acute Care Syndromic Testing Market?
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Acute Care Syndromic Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company
Tele Intensive Care Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report
Severe Acute Respiratory Syndrome Treatment Market Report 2026
Tele Intensive Care Unit Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model